gemcitabine has been researched along with Malignant Mesothelioma in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 28 (75.68) | 24.3611 |
| 2020's | 9 (24.32) | 2.80 |
| Authors | Studies |
|---|---|
| Bonelli, C; Boni, L; Bonomi, M; Cappuzzo, F; Ceresoli, GL; de Marinis, F; Frega, S; Garassino, MC; Gervasi, E; Gianoncelli, L; Grossi, F; Grosso, F; Maconi, A; Pagano, M; Pasello, G; Pedrazzoli, P; Perrino, M; Pinto, C; Santoro, A; Soto Parra, H; Tiseo, M; Zanelli, F; Zucali, PA | 1 |
| Abo Elkasem, F; Bahnassy, A; Gaafer, R; Khorshid, O; Wahba, NI | 1 |
| Cordua, N; D'Antonio, F; De Vincenzo, F; Giordano, L; Perrino, M; Santoro, A; Zucali, PA | 1 |
| Drevinskaite, M; Kevlicius, L; Mickys, U; Patasius, A; Smailyte, G | 1 |
| Assaraf, YG; Avan, A; Braczko, A; Cascioferro, S; Cloos, J; Deraco, M; Diana, P; El Hassouni, B; Funel, N; Giovannetti, E; Granchi, C; Jansen, G; Lagerweij, T; Li Petri, G; Mantini, G; Matherly, LH; Minutolo, F; Parrino, B; Peters, GJ; Sciarrillo, R; Smid, K; Smolenski, RT; Zaffaroni, N; Zeeuw van der Laan, EA; Zucali, PA | 1 |
| Doi, H; Ishigaki, H; Kijima, T; Kitajima, K; Koda, Y; Kuribayashi, K; Minami, T; Nakajima, Y; Nakamura, A; Takahashi, R; Yokoi, T | 1 |
| Nowak, AK | 1 |
| Aerts, JG; Baas, P; Biesma, B; Bootsma, GP; Buikhuisen, WA; Burgers, JA; Cornelissen, R; Dammeijer, F; de Gooijer, CJ; den Brekel, AJS; Groen, HJM; Lalezari, F; Soud, MY; Stigt, JA; van der Noort, V; van Heemst, RC; van Tinteren, H; van Walree, N | 1 |
| Bosch-Barrera, J; Cedrés, S; Coves, J; de Castro-Carpeño, J; García-Campelo, R; Guirado, M; López-Castro, R; Nadal, E; Ortega, AL; Vicente, D | 1 |
| Dolžan, V; Goričar, K; Kovač, V | 1 |
| De, A; Jacobson, BA; Jay-Dixon, J; Kratzke, MG; Kratzke, RA; Patel, MR; Peterson, MS; Sadiq, AA | 1 |
| Bode, B; Britschgi, C; Cecconi, V; Curioni-Fontecedro, A; Felley-Bosco, E; Friess, M; Hiltbrunner, S; Opitz, I; Soldini, D; Stahel, RA; Stolzmann, P; Tallón de Lara, P; Tischler, V; van den Broek, M; Vrugt, B; Weder, W; Yagita, H | 1 |
| Alhebshi, H; Bakker, E; Demonacos, C; Guazzelli, A; Hussain, M; Krstic-Demonacos, M; Meysami, P; Mutti, L; Schwartz, JM; Tian, K | 1 |
| Bakker, E; Demonacos, C; Giordano, A; Guazzelli, A; Krstic-Demonacos, M; Meysami, P; Mutti, L | 1 |
| Fahmy, ES; Habib, EE | 1 |
| Biffo, S; Burlando, B; Gallo, S; Martinotti, S; Mutti, L; Ranzato, E; Russo, MV; Volta, V | 1 |
| Abou-Elela, E; Darwish, D; Ibrahim, N | 1 |
| Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM | 1 |
| Akca, Z; Aksahin, A; Aslan, T; Berk, V; Buyukcelik, A; Erden, A; Karaca, H; Mutlu, H; Ozkan, M | 1 |
| Brahmbhatt, H; Cheng, YY; Edelman, JJ; Kirschner, MB; Klebe, S; MacDiarmid, JA; McCaughan, BC; Mugridge, N; Pel, ME; Reid, G; Vallely, MP; van Zandwijk, N; Weiss, J; Williams, M; Wright, C | 1 |
| Hirai, F; Ichinose, Y; Inamasu, E; Kojo, M; Morodomi, Y; Seto, T; Shimokawa, M; Shiraishi, Y; Takenaka, T; Takenoyama, M; Toyokawa, G; Toyozawa, R; Yamaguchi, M | 1 |
| Akamatsu, H; Endo, M; Imai, H; Kenmotsu, H; Murakami, H; Naito, T; Ono, A; Shukuya, T; Taira, T; Takahashi, T; Tokito, T; Yamamoto, N | 1 |
| Arrieta, O; Bacon-Fonseca, L; Blake-Cerda, M; Corona-Cruz, JF; López-Macías, D; Macedo-Pérez, EO; Mendoza-García, VO; Muñiz-Hernández, S; Muñoz-Montaño, W | 1 |
| Ginsberg, MS; Kass, SL; Krug, LM; Sima, CS; Woo, K; Zauderer, MG | 1 |
| Arslan, A; Baran, M; Cihan, YB; Deniz, K; Karaca, H; Ozturk, A | 1 |
| Akca, Z; Büyükçelik, A; Cihan, YB; Coşkun, HS; Erden, A; Gündüz, S; Karaca, H; Mutlu, H | 1 |
| Akaihata, M; Hosoya, M; Kikuta, A; Kobayashi, S; Mochizuki, K; Ohara, Y; Sano, H; Waragai, T | 1 |
| Frischknecht, L; Meerang, M; Moch, H; Opitz, I; Seifert, B; Soltermann, A; Stahel, R; Weder, W | 1 |
| Ak, G; Akarsu, M; Metintas, M; Metintas, S | 1 |
| Felley-Bosco, E; Friess, M; Frischknecht, L; Korol, D; Opitz, I; Soltermann, A; Stahel, R; Thies, S; Vrugt, B; Weder, W | 1 |
| Ceresoli, GL; Zucali, PA | 1 |
| Debus, J; Hoffmann, H; Huber, PE; Nicolay, NH; Roeder, F; Safi, S; Sterzing, F; Thieke, C | 1 |
| Berns, A; Bianchi, ME; Boldorini, R; Ceriotti, C; Crippa, L; Crippa, MP; D'Incalci, M; de Vries, H; Doglioni, C; Frapolli, R; Frenquelli, M; Gatti, E; Marchis, FD; Mezzapelle, R; Moresco, RM; Pecciarini, L; Perani, L; Preti, A; Recordati, C; Rrapaj, E; Scanziani, E; Spinelli, AE; Valtorta, S; Venturini, M | 1 |
| Akin, O; Arslan, A; Deniz, E; Ozcakir-Tomruk, C | 1 |
| Astorgues-Xerri, L; Bekradda, M; Bello, E; Cvitkovic, E; D'Incalci, M; Erba, E; Frapolli, R; Grosso, F; Lettera, E; Libener, R; Licandro, SA; Orecchia, S; Panini, N; Riveiro, ME; Romano, M; Ubezio, P; Vázquez, R | 1 |
| Chen, X; Guo, R; Jin, S; Liu, Y; Ping, G; Røe, OD; Shu, Y; Yan, K; Yin, Y | 1 |
| Armato, SG; Dignam, JJ; Kindler, HL; Labby, ZE; Nowak, AK; Straus, C | 1 |
3 review(s) available for gemcitabine and Malignant Mesothelioma
| Article | Year |
|---|---|
Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature.
Topics: Aged; Antineoplastic Agents; Biopsy; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymphadenopathy; Male; Mesothelioma; Mesothelioma, Malignant; Orchiectomy; Pemetrexed; Prognosis; Testicular Hydrocele; Testicular Neoplasms | 2020 |
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
Topics: Antineoplastic Agents; Asbestos; Carcinogens; Combined Modality Therapy; Cytoreduction Surgical Procedures; Deoxycytidine; Gemcitabine; Genetic Testing; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Medical Oncology; Mesothelioma, Malignant; Neoplasm Staging; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Radiotherapy; Societies, Medical; Spain; Vinorelbine | 2021 |
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Pleural Neoplasms; Vinblastine; Vinca Alkaloids; Vinorelbine | 2015 |
8 trial(s) available for gemcitabine and Malignant Mesothelioma
| Article | Year |
|---|---|
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Male; Mesothelioma, Malignant; Middle Aged; Pleural Neoplasms; Progression-Free Survival; Ramucirumab; Time Factors | 2021 |
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Imatinib Mesylate; Male; Mesothelioma, Malignant; Pemetrexed; Pleural Neoplasms; Prognosis; Salvage Therapy; Survival Rate | 2020 |
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesothelioma, Malignant; Netherlands; Pemetrexed; Prospective Studies; Treatment Outcome | 2021 |
Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Models, Biological; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Pemetrexed; Pharmacogenomic Testing; Polymorphism, Genetic; Precision Medicine; Survival Rate | 2017 |
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2013 |
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Prognosis; Quality of Life; Survival Analysis | 2014 |
Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Organoplatinum Compounds; Pemetrexed; Pleural Neoplasms; Survival Analysis | 2015 |
26 other study(ies) available for gemcitabine and Malignant Mesothelioma
| Article | Year |
|---|---|
The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Endonucleases; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Prospective Studies; Thymidylate Synthase; Treatment Outcome | 2023 |
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
Topics: Animals; Antigens, Neoplasm; Carbonic Anhydrase IX; Cell Culture Techniques; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; L-Lactate Dehydrogenase; Mesothelioma, Malignant; Mice; Pemetrexed; Peritoneal Neoplasms; Pleural Neoplasms; Proton-Coupled Folate Transporter; Xenograft Model Antitumor Assays | 2020 |
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leukopenia; Male; Mesothelioma, Malignant; Middle Aged; Neutropenia; Pemetrexed; Platinum; Progression-Free Survival; Retrospective Studies; Thrombocytopenia | 2021 |
New and old treatments for malignant mesothelioma: not just immunotherapy.
Topics: Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mesothelioma, Malignant; Pleural Neoplasms | 2021 |
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
Topics: Adaptor Proteins, Signal Transducing; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4F; Eukaryotic Initiation Factor-4G; Gemcitabine; Genome, Human; Humans; Hydrazones; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Phosphoproteins; Phosphorylation; Pleural Neoplasms; Polyribosomes; Protein Binding; Protein Biosynthesis; Proteome; Reproducibility of Results; RNA Caps; Thiazoles | 2018 |
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression; Humans; Immunomodulation; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Positron Emission Tomography Computed Tomography; Prognosis; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
Topics: Cell Line, Tumor; Cell Survival; Deoxycytidine; Etoposide; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Models, Biological; Neoplasm Staging; Pleural Neoplasms; Proportional Hazards Models; Transcriptome; Tumor Suppressor Protein p53; Wound Healing | 2018 |
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mutation; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2019 |
Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Catechin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Inbred NOD; Mice, SCID; Pleural Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Survival of mesothelioma in a palliative medical care unit in egypt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Egypt; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Morphine; Pain; Palliative Care; Pleural Neoplasms; Quality of Life; Retrospective Studies; Survival; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid | 2013 |
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Palliative Care; Pemetrexed; Platinum; Pleural Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Pemetrexed; Pleural Neoplasms; RNA Interference; Transfection; Tumor Burden | 2013 |
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Vinblastine; Vinorelbine | 2014 |
Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neutropenia; Pemetrexed; Pleural Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pleural Neoplasms; Retrospective Studies; Salvage Therapy; Vinblastine; Vinorelbine | 2014 |
ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Retrospective Studies; Treatment Outcome | 2014 |
Malignant peritoneal mesothelioma in a child: chemotherapy with gemcitabine and platinum was effective for the disease unresponsive to other treatments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Child; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Peritoneal Neoplasms | 2014 |
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Pneumonectomy; Predictive Value of Tests; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nestin; Pemetrexed; Platinum; Pleural Neoplasms; Pneumonectomy; Prognosis; Sarcoma; Stem Cell Factor | 2015 |
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Pleural Neoplasms; Pneumonectomy; Proportional Hazards Models; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Treatment Outcome | 2015 |
Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; Female; Gemcitabine; HMGB1 Protein; Humans; Immunocompetence; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice, Inbred BALB C; Neoplasm Transplantation; Pemetrexed; Survival Analysis | 2016 |
A case report of metastasis of malignant mesothelioma to the retromolar trigone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calbindin 2; Cisplatin; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Fluorodeoxyglucose F18; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Mouth Neoplasms; Pemetrexed; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Radiography, Panoramic; Radiotherapy, Adjuvant | 2016 |
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Topics: Acetanilides; Aged; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice; Middle Aged; Pemetrexed; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays | 2017 |
Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Neoplasm Staging; Pleural Effusion, Malignant; Recombinant Proteins; Secondary Prevention; Severity of Illness Index; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
Topics: Aged; Aged, 80 and over; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Prognosis; Tomography, X-Ray Computed; Treatment Outcome | 2013 |